U.S. FDA approves Biogen's multiple sclerosis drug, Tecfidera

March 27 Wed Mar 27, 2013 3:42pm EDT

March 27 (Reuters) - U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.

Combined clinical trial data showed Tecfidera, formerly known as BG-12, cut the average relapse rate by 49 percent after two years compared to patients taking a placebo.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.